Muscular Dystrophies
Conditions
Keywords
Muscle Weakness, Muscular Dystrophy
Brief summary
This is a study to determine whether albuterol or oxandrolone, alone or in combination, are able to increase strength and muscle mass in patients with FSHD. It also will determine if albuterol given in pulsed fashion will have more effect than when given continuously.
Detailed description
Patients will be randomized to 1 of 4 groups: placebo, pulsed albuterol, oxandrolone, or both pulsed albuterol and oxandrolone. Treatment will continue for 52 weeks unless unacceptable side effects occur. Patients will undergo testing of muscle function. All patients will return for follow-up assessments at Weeks 4, 12, 26, and 52.
Interventions
DRUGAlbuterol
DRUGOxandrolone
Sponsors
FDA Office of Orphan Products Development
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Presence of 4q35 small fragment of less than 40 kb by standard DNA testing * Weakness of the facial muscles, including frontalis, orbicularis oculi, or orbicularis oris * Weakness of scapular stabilizers or foot dorsiflexors * Ambulatory * Weakness grade 2 or worse in the arm using upper extremity grading scale
Exclusion criteria
* Prior use of oral beta-2 agonists for a period of at least 1 year or within the past 3 months * Concurrent use of other sympathomimetic agents, antidepressants, or beta-2 receptor blockers * Pregnancy * Known hypersensitivity to anabolic steroids * Any medical or psychological condition that would interfere with the study * Requirement for a wheelchair
Countries
United States
Outcome results
None listed